July 2025 in “Malaria Journal” Resolving malaria-related lung issues doesn't rely on Alox12 and leaves some inflammation.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
3 citations
,
October 2025 in “Biomedicines” New treatments for seborrheic dermatitis show promise for difficult cases.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
46 citations
,
April 2020 in “Drugs” Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
1 citations
,
October 2017 JAK inhibitors are effective for hair regrowth in severe alopecia areata.
2 citations
,
January 2023 in “Pharmaceuticals” Natural products and phytochemicals may help with hair regrowth, but more research is needed.
November 2025 in “Biomedicines” Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
November 2025 in “Biomedicines” JAK1 inhibitors can help reduce itchiness in atopic dermatitis.
21 citations
,
July 2022 in “Orphanet journal of rare diseases” New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.
3 citations
,
July 2023 in “International journal of molecular sciences” Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
2 citations
,
May 2025 in “IntechOpen eBooks” Early treatment with corticosteroids and immunosuppressants is crucial for managing Vogt-Koyanagi-Harada disease.
New hair regrowth therapies show promise but need more research.
April 2024 in “Journal of clinical medicine” Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
88 citations
,
August 2019 in “Frontiers in immunology” Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
57 citations
,
August 2023 in “American Journal of Clinical Dermatology” JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.
15 citations
,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
1 citations
,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.
June 2025 in “Academic Medical Journal” Vitiligo treatments are improving but relapses are common.
August 2022 in “IntechOpen eBooks” The best treatment for Frontal Fibrosing Alopecia and Lichen Planopilaris combines oral and topical medications to reduce symptoms and stop hair loss.
New treatments show promise for hair loss, especially JAK inhibitors for alopecia areata.
1 citations
,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
138 citations
,
June 2023 in “Molecules” Skin pigmentation varies due to genetics, UV exposure, and drugs, with treatments available but requiring medical advice.
38 citations
,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
32 citations
,
May 2023 in “Preprints.org” Skin pigmentation varies due to genetics, UV exposure, and medications, with treatments available but requiring medical advice.
15 citations
,
July 2022 in “Frontiers in Pharmacology” Cepharanthine may help treat COVID-19 by targeting similar pathways as other inflammatory diseases.